During viral replication, the innate immune response is induced through the recognition of viral replication intermediates by host factor(s). One of these host factors, cyclic GMP-AMP synthetase (cGAS), was recently reported to be involved in the recognition of viral DNA derived from DNA viruses. However, it is uncertain whether cGAS is involved in the recognition of hepatitis B virus (HBV), which is a hepatotropic DNA virus. In the present study, we demonstrated that HBV genome-derived dsDNA induced the innate immune response through cGAS and its adaptor protein, STING, in human hepatoma Li23 cells expressing high levels of cGAS. In addition, we demonstrated that Page 4 HBV infection induced ISG56 through the cGAS-STING signaling pathway. This signaling pathway also showed an antiviral response towards HBV through the suppression of viral assembly. From these results, we conclude that the cGAS-STING signaling pathway is required for not only the innate immune response against HBV but also the suppression of HBV assembly. The cGAS-STING signaling pathway may thus be a novel target for anti-HBV strategies.
Introduction
Hepatitis B virus (HBV) is an enveloped double-stranded DNA (dsDNA) (3.2 kilobase; kb) virus classified into the Hepadnaviridae family. Chronic hepatitis is caused not only by hepatitis C virus (HCV) but also by HBV, and then progresses to liver cirrhosis and hepatocellular carcinoma. Since approximately 350 million people are infected with HBV worldwide, HBV infection is a serious global health problem [1, 2] . These diseases are tightly associated with inflammation caused by persistent HBV infection in the liver. To suppress the progression of hepatic diseases, it is necessary to prevent persistent HBV infection. However, HBV is known to evade the host innate immune response for persistent infection [3, 4] .
HBV has a relaxed circular DNA (rcDNA) as a viral genome [5, 6] . Following the invasion of HBV to hepatocytes, intracellular HBV rcDNA is converted to a covalently closed circular DNA (cccDNA) by DNA repair machinery. The transcription from the cccDNA is controlled by liver-enriched transcriptional factors [7, 8] . Four viral single-stranded RNAs (ssRNAs; 3.5, 2.4, 2.1, and 0.7 kb) are transcribed from HBV cccDNA. Among these viral ssRNAs, 3.5 kb RNA functions as an HBV pregenomic RNA (pgRNA). By the reverse transcriptase activity of HBV DNA polymerase, a negative-stranded DNA is synthesized from HBV pgRNA, and subsequently HBV rcDNA is formed by the synthesis of positive-stranded DNA from negative-stranded DNA. HBV rcDNA contains four open-reading frames (ORFs) encoding preS1/preS2/S (S), precore/core (C) , polymerase (P), and X antigen genes (known as S gene, C gene, P gene, and X gene, respectively). S gene encodes three envelop proteins of different sizes; Large S (prepreS1/preS2/S), Middle S (preS2/S), and Small S (S), respectively. P gene encodes DNA polymerase responsible for the reverse transcription of HBV pgRNA [5, 6] .
During the life cycle of HBV, viral dsDNA (rcDNA and cccDNA), viral single-stranded DNA (ssDNA; positive or negative strand) and four viral ssRNAs are produced as viral replication intermediates. Since HBV replication contains the step of reverse transcription, it has been predicted that a DNA:RNA duplex is produced as a viral replication intermediate [5] . Very recently, the RNA sensor RIG-I was reported to induce the innate immune response through recognition of the 5'-εregion of HBV pgRNA [9] . However, the host recognition mechanism toward HBV DNA remains unclear. One of the DNA sensors, cyclic GMP-AMP synthetase (cGAS), was recently reported to recognize cytosolic DNA, and to induce the activation of transcription factor IRF-3 and subsequently the production of interferon (IFN)-β and numerous IFN-stimulated genes (ISGs) such as ISG56 (also known as IFIT1) and ISG15 in a STING (adaptor protein of cGAS)-dependent manner (this sequence is known as the cGAS-STING signaling pathway) [10] . The cGAS-STING signaling pathway was also required for the recognition of infection with several viruses such as herpes simplex virus type 1 (HSV-1) [11] , vaccinia virus (VACV) [11] , and human immunodeficiency virus (HIV) [12] . Therefore, we presumed that the cGAS-STING signaling pathway is Page 7 involved in the recognition of HBV infection. To evaluate this presumption, we examined whether the cGAS-STING signaling pathway is required for the recognition of HBV using human hepatoma Li23 cells [13] and HBV-replicating HepG2.2.15 cells [14] .
Here, we show that the cGAS-STING signaling pathway is required for the innate immune response against HBV, and that this signaling pathway is also involved in the suppression of HBV assembly.
Results

The synthetic analogues of Z-form DNA, p-dGdC, induced ISG56 in Li23 cells
Host cells induce the innate immune response through the recognition of viral replication intermediates. Very recently, the RNA sensor, RIG-I, was reported to recognize the 5'- region of HBV pgRNA [9] . However, the host recognition mechanism toward HBV DNA is uncertain. To clarify this mechanism, hepatic cell lines showing an innate immune response to HBV DNA were required. Therefore, we first RIG-I/IPS-1-mediated signaling pathway through the cleavage of IPS-1 [19, 20] . Therefore, using Li23 cells stably expressing exogenous HCV NS3/4A (designated Li23 NS3/4A cells), we examined whether p-dGdC and p-dAdT induced ISG56 through the RIG-I/IPS-1-mediated signaling pathway. The results revealed that NS3/4A did not prevent ISG56 induction by p-dAdT, although that by p-IC was absolutely prevented by NS3/4A (left and central panels in Fig. 1A ). NS3/4A also did not inhibit ISG56 induction by p-dGdC (right panel in Fig. 1A) . These results suggest that the dsDNA-triggered signaling pathway is distinct from the RIG-I/IPS-1-mediated signaling pathway in Li23 cells.
On the other hand, it was reported that cytosolic DNA was recognized by cGAS and subsequently induced the innate immune response [10] [11] [12] . Therefore, we examined the expression levels of cGAS in several human hepatic cell lines, including Li23. We obtained the interesting result that cGAS mRNA was highly expressed in only NKNT-3 and Li23 cells (Fig. 1B ). This result is in accord with the former result that only NKNT-3 and Li23 cells were able to recognize p-dGdC (Table 1) . Therefore, we next examined whether cGAS is required for the p-dGdC-triggered signaling pathway. The results revealed that p-dGdC-triggered ISG56 induction was remarkably prevented in cGAS-knockdown Li23 cells ( Fig. 1C and right panel in Fig. 1D ). Since p-dAdT, but not p-IC-triggered ISG56 induction was also significantly prevented in the cGAS-knockdown cells (central and left panels in Fig. 1D ), we inferred that the p-dAdT-triggered signaling pathway was also partially regulated by cGAS in Li23 cells.
It has been also reported that cGAS activates its downstream transcription factor, IRF-3, and subsequently induces IFN-β and ISGs through the association with its adaptor protein, STING [10] . Therefore, we examined whether STING and IRF-3 were required for the p-dGdC-or p-dAdT-triggered signaling pathway in Li23 cells. The results revealed that STING-( Fig. 2A ) and IRF-3-knockdown ( Fig. 2B ) Li23 cells greatly weakened both p-dGdC-and p-dAdT-triggered ISG56 induction (Figs. 2C and 2D). Taken together, these results lead us to suggest that the cGAS-STING signaling pathway is required for the recognition of p-dGdC, and that this pathway is partially involved in the recognition of p-dAdT.
HBV triggered the cGAS-STING signaling pathway
It has been reported that the cGAS-STING signaling pathway functions as an antiviral sensor for infection with DNA viruses such as HSV-1 and VACV [11] . Therefore, we used several synthetic dsDNAs, including HBV-derived dsDNA, to examine whether the cGAS-STING signaling pathway is required for the recognition of HBV dsDNA Since HepG2 cells showed defective NTCP expression, we prepared HepG2/NTCP-myc cells stably expressing both exogenous cGAS or cGAS GSAA, and STING in addition to NTCP containing myc tag (designated HepG2/NTCP-myc cGAS/STING and HepG2/NTCP-myc cGAS GSAA/STING cells) for an experiment on HBV infection.
We also prepared an HBV inoculum by concentrating the supernatant of HepG2.2.15 cells (designated HBVcc; cell-cultured HBV). At 13 days after HBVcc infection, we observed that ISG56 was induced in HepG2/NTCP-myc cGAS/STING cells, but not in
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HepG2/NTCP-myc cGAS GSAA/STING cells (Fig. 4E ). These results suggest that HBV triggered the cGAS-STING signaling pathway.
The cGAS-STING signaling pathway showed an antiviral response towards HBV through the suppression of viral assembly
To evaluate the antiviral response toward HBV through the cGAS-STING pathway, we first examined the level of HBV RNA in HepG2. Fig. 6B ). Moreover, we found that the extracellular HBV DNA and the infectivity of extracellular HBVcc were reduced only in HepG2.2.15 cGAS/STING cells (Fig. 6C ). From these results, we conclude that the cGAS-STING signaling pathway negatively regulates the viral assembly.
Low expression of endogenous cGAS in Li23 cells increased the permissiveness to
Our findings that HBV triggered an antiviral response through the cGAS-STING signaling pathway suggested that the expression level of endogenous cGAS might affect the permissiveness to HBV infection. To investigate this possibility, we first prepared Li23/NTCP-myc cells stably expressing NTCP containing a myc tag, and then established dozens of subcloned cell lines by the limited dilution of Li23/NTCP-myc cells to obtain cell lines showing different levels of cGAS expression. Among the obtained cell lines, we selected A7 cells, which showed the highest level of cGAS expression, and A8 cells, which showed the lowest level of cGAS expression ( Fig. 7A ).
An HBV infection experiment using A7 and A8 cells in addition to parental Li23/NTCP-myc cells revealed that the permissiveness to HBV infection in A7 cells was lower than that in the parental cells and the permissiveness in A8 cells was higher than that in the parental cells ( Fig. 7B ). At 13 days after HBVcc infection, we also observed that ISG56 was induced in A7 cells, but not in A8 cells (Fig. 7C ). In addition, we observed that B34 and B48 subcloned cells, which showed a low level of cGAS expression equivalent to that in A8 cells (Fig. S1A) , also showed higher permissiveness to HBV infection than that in the parental cells (Fig. S1B ). These results also suggest Page 16 that cGAS is a host factor which may regulate the permissiveness to HBV infection.
Discussion
The DNA double helix is known to form a right-handed conformation (i.e., A-form or induced the innate immune response, and p-dGdC (Table 1) , HBV-, HSV-1-or VACVderived dsDNA (data not shown) was not absolutely recognized. These results suggest that the synthetic HBV-derived dsDNA as well as HSV-1-or VACV-derived dsDNA takes the conformation of Z-form in the cells. According to other groups, the cGAS-STING signaling pathway was required for the recognition of several viruses, such as HSV-1 [11] , VACV [11] , and HIV [12] . We also demonstrated that the cGAS-STING signaling pathway was required for the recognition of HBV dsDNA, and functioned as an antiviral mechanism through the induction of ISG56 (Figs. 4C and 4E).
These results imply that cGAS may play an important role in the recognition of Z-form DNA, such as viral replication intermediates produced from DNA virus as "non-self" DNA ( Fig. 7D) .
The cGAS-STING signaling pathway also suppressed the infectivity of intracellular HBV without a reduction of intracellular HBV DNA (Fig. 6B ). This result suggests that the cGAS-STING signaling pathway may negatively regulate the viral assembly. The 5'-cap structure of HBV pgRNA is essential for viral encapsidation [27] . On the other hand, ISG56 is known to inhibit the replication of some viruses by inhibiting viral translation through binding to the 5'-cap structure of viral RNA [15] . Further analysis is needed to clarify whether the cGAS-STING signaling pathway inhibits viral encapsidation or viral translation through the binding of ISG56 to the 5'-cap structure of HBV pgRNA.
Recently it was reported that both HBV and HCV were able to replicate and proliferate in a newly developed hepatoma cell line, HLCZ01 [28] . This result implies that the common important host factor or factors for the complete life cycles of both HBV and HCV are present in hepatocyte. We previously found that human hepatoma HuH-7-derived RSc cells and Li23-derived ORL8c cells showed higher permissiveness of HCV than their parental HuH-7 and Li23 cells, respectively [13, 29] . In the present study, we demonstrated that the high permissiveness to HBV infection was related to lower cGAS expression using several cell lines subcloned from Li23/NTCP-myc cells ( Figs. 7A and 7B, and Fig. S1 ). In this context, interestingly, Li23-derived ORL8c cells
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showed defective expression of cGAS and showed no responsiveness to p-dGdC (data not shown). From these results, it is predicted that ORL8c cells possess an environment that is advantageous to HBV multiplication. ORL8c may be a useful cell line for the development of both HBV and HCV-replicating cells.
Experimental procedures
Cell cultures and reagents
Human hepatoma Li23 cells [13] were cultured in modified medium for human immortalized hepatocyte PH5CH8 cells [30] as previously described [13] . Other human immortalized hepatocytes, NKNT-3 [31] and OUMS-29 cells [32] , which were kindly provided by Drs. Noriyuki Kobayashi and Masayoshi Namba (Okayama University), were also maintained in this modified medium for human immortalized hepatocytes. with 10% fetal bovine serum as previously described [16, 18] . Li23 NS3/4A cells were maintained in medium including blasticidin as previously described [19, 33] .
HepG2.2.15 cells [14] were kindly provided by Dr. Takaji Wakita (National Institute of Infectious Disease, Tokyo, Japan).
HepG2/NTCP-myc cells and Li23/NTCP-myc cells were prepared by the retroviral transfer of myc-tagged NTCP. Limited dilution of Li23/NTCP-myc cells were performed to establish the subcloned cell lines.
In vitro synthesized ligands such as p-IC, 5'-ppp dsRNA, p-dGdC, and p-dAdT were purchased from InvivoGen (San Diego, CA, USA). Synthetic dsDNA derived from HSV-1 and VACV were also purchased from InvivoGen. In vitro synthesized p-AdT was purchased from The Midland Certified Reagent Company (Midland, TX, USA).
Quantitative RT-PCR analysis
In vitro synthesized ligands were complexed with Lipofectamine 2000 (Invitrogen) for Page 21 the transfection as previously described [19] . Total cellular RNA was isolated from the cells at 6 h after transfection by using an RNeasy Mini Kit (Qiagen, Hilden, Germany).
RT was performed as previously described [33] . For quantitative PCR, we used a SYBR Premix Ex Taq Kit (TaKaRa Bio, Otsu, Japan) and the following primer sets: for ISG56 [34] , IRF-3 [19] , and GAPDH [35] . We also prepared the following forward and reverse primer sets for cGAS, 5'-AAGCTCCGGGCGGTTTTGGA-3' (forward) and 
Synthetic HBV dsDNA
Two oligonucleotides (nt 1750-1795 according to C_JPNAT clone with accession no.
AB246345) [36] derived from the positive-or negative-stranded HBV DNA were synthesized in vitro. These oligonucleotides were annealed by heating at 70 degrees for 10 minutes followed by slow cooling to room temperature. The annealed product was confirmed by agarose gel electrophoresis.
Generation of cells stably expressing exogenous cGAS or STING
To construct pCX4bsr/HA-cGAS and pCX4pur/Myc-STING retroviral vectors, we introduced cGAS (accession no. NM_138441) and STING (accession no. NM_198282) cDNA containing a full-length ORF into the pCX4bsr/HA or pCX4pur/Myc retroviral vector, respectively, as previously reported [37] . These vectors were simultaneously introduced into HepG2.2.15 cells, HepG2 cells or HepG2/NTCP-myc cells by the retroviral transfer and subsequently selected the cells stably expressing exogenous cGAS and STING by blasticidin and puromycin. We also introduced both pCX4bsr and pCX4pur vectors into cells as control cells. At 3 days after transfection, total cellular RNA, and the cell lysate were prepared from both these cells. The exogenous expression of cGAS and STING were confirmed by the quantitative RT-PCR or Western blot analysis using anti-HA (Cell Signaling Technology, Beverly, MA, USA) antibodies as previously described [34] .
Page 24
HBV infection
HBVcc was prepared from the supernatant of HepG2. hr. At 24 hr after the inoculation, the culture medium was replaced with fresh medium.
Analysis of HBV DNA
For analysis of the intracellular HBV DNA, total cellular DNA was isolated by The supernatant of HepG2-derived cells was also used for the inoculation to
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HepG2/NTCPmyc cells in culture medium containing 4% PEG 8000 and 2% DMSO.
At 4 days after the inoculation, total RNA was isolated by using an RNeasy Mini Kit (Qiagen). Quantitative RT-PCR analysis of HBV RNA was performed to evaluate the viral infectivity of the supernatant as described below.
Analysis of HBV RNA
For the analysis of the intracellular HBV RNA, total RNA was isolated by using an RNeasy Mini Kit (Qiagen), and was subjected to Northern blot analysis. Total RNA was separated on 0.8% agarose gel and then transferred to a Hybond-N+ membrane (GE Healthcare) using a standard transfer procedure. DIG-labeled HBV plus-stranded specific riboprobe was prepared from pTZ19R 1426-1896 (corresponding to the sense strand of HBV DNA; nts 1426-1896 of the D_IND60 clone) using a T7 Megascript kit (Ambion, Austin, TX) and DIG RNA labeling mix (Roche). The transferred membrane was hybridized with the DIG-labeled HBV plus-stranded specific riboprobe, and then HBV RNA was detected using anti-DIG antibody (Roche).
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Quantitative RT-PCR analysis of HBV RNA was performed as previously reported [21] . pC_JPNAT plasmid DNA [36] was used as a standard to calculate the amount of HBV RNA. Data are the means ± SD from three independent experiments.
Statistical analysis
The significance of differences among groups was determined using Student's t-test.
P<0.05 was considered statistically significant. The level of ISG56 mRNA was calculated relative to the level in Li23 cells without ligand treatment (-), which was set at 1. 
Figure Legends
